Zhejiang Teruisi Pharmaceutical Inc.

Quick facts

Phase 3 pipeline

• China-approved Bevacizumab · Oncology
  Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.
• TRS003

Phase 2 pipeline

• TRS005

Phase 1 pipeline

• US-licensed Avastin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Zhejiang Teruisi Pharmaceutical Inc. portfolio CI brief
• Zhejiang Teruisi Pharmaceutical Inc. pipeline updates RSS